NEWSLETTER

Cancer non metastatic, Cancerul pulmonar - principala cauză de deces în lume

Conținutul

    Primary Outcome Measures: 1. To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 6 months 7.

    recenzii despre virusul papilomului uman

    To determine the profile of cancer non metastatic treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 12 months 8. Cancer non metastatic determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 18 months 9.

    To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 24 months To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph node involvement, stage, grade, chemotherapy, radiotherapy 30 human papilloma virus biological if applicable To determine the profile of patients treated with Aromasin® age, type of tumour, type of surgery, hormone receptors, lymph cancer non metastatic involvement, stage, grade, chemotherapy, radiotherapy 36 months if applicable To evaluate compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 6 months To evaluate compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards cancer non metastatic therapy or chemotherapy 12 months To evaluate compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 18 months To cancer non metastatic compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 24 months To evaluate compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 30 months if applicable To evaluate compliance and the reasons for any discontinuation of Aromasin® therapy and the type of treatment administered afterwards hormonal therapy or chemotherapy 36 months if applicable To evaluate the rate of treatment discontinuation 6 months To evaluate the rate of treatment discontinuation 12 months To evaluate the rate of treatment discontinuation 18 months To evaluate the rate of treatment discontinuation 24 months To evaluate the rate of treatment discontinuation 30 months if applicable To evaluate the rate of treatment discontinuation 36 months if applicable To evaluate recurrence-free survival time from the inclusion to date of confirmation of any recurrence - as local or recunoaște condiloamele recurrence; new primary ipsilateral or controlateral breast cancer, death and time to disease progression.

    condiloame în locuri intime tratament